Merck & Co identifies supply of nitrosamine in diabetes medicine | Enterprise
US pharmaceutical large Merck & Co has discovered the reason for nitrosamine contaminants in three profitable diabetes medicine that comprise the energetic ingredient sitagliptin. Nitrosamine impurities have the potential to trigger most cancers and have come below growing scrutiny by regulators following their detection in a wide range of medicine in recent times. Merck confirmed …
Merck & Co identifies supply of nitrosamine in diabetes medicine | Enterprise Read More »